Alcon launches Hydrus Microstent in India to transform glaucoma care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Germany will be the first launch market
The first of four planned modules at the new plant is expected to come online by summer 2026
Subscribe To Our Newsletter & Stay Updated